WASHINGTON (CN) - The Food and Drug Administration plans to reclassify the external pacemaker, so manufacturers have to follow "special controls" in a guidance document instead notifying the FDA when the manufacturer will be marketing the product.
An external pacemaker is used as a temporary substitute for the heart's intrinsic pacing system until a permanent pacemaker can be implanted, or to control irregular heartbeats in patients following cardiac surgery or a heart attack. It produces a periodic electrical pulse to make the heart pump blood.
In 2009, the FDA requested information on the devices, and it received reclassification petitions from three device manufacturers. The manufacturers stated that safety and effectiveness of these devices may be assured by design and maintenance (special controls), consideration of risks involved with the device, and an independent verification that appropriate standard operating procedures are in place and being followed.
Click the document icon for this regulation and others.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.
Additional Reads
-
FDA approves over-the-counter Narcan. Here's what it means March 29, 2023 -
TikTok sends influencers to Washington as its troubles grow March 22, 2023
-
Durbin puts FDA on blast over unauthorized vape sales March 16, 2023 -
FDA: Two more eyedrop brands recalled due to risks March 7, 2023